HAE vs PHVS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HAE and PHVS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HAE and PHVS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Haemonetics Corporation, based in Boston and listed on the NYSE, has sold blood-handling technology since 1971. Its largest business is plasma: the NexSys PCS apheresis machines, and the far more profitable single-use disposable kits that run on them, sit in the collection centers operated by companies like Grifols, Takeda's BioLife and Octapharma, which turn donated plasma into immunoglobulin and other plasma-derived therapies. A second business, grouped under the hospital umbrella, splits into Interventional Technologies (the VASCADE and VASCADE MVP vascular closure devices used after catheter procedures, plus the OpSens optical pressure sensing line and the Attune Medical esophageal cooling device) and Blood Management Technologies (TEG viscoelastic hemostasis analyzers, Cell Saver autotransfusion systems, and blood-tracking software). A third and shrinking business supplies whole-blood and apheresis collection to blood banks.

Full HAE guide

Pharvaris N.V. is a Dutch biopharmaceutical company headquartered in Leiden and listed on Nasdaq as PHVS. It works on one disease: hereditary angioedema (HAE), a rare genetic condition in which uncontrolled bradykinin signaling causes sudden, unpredictable and sometimes life-threatening swelling attacks. Its lead candidate, deucrictibant, is a small-molecule oral bradykinin B2 receptor antagonist developed in two formulations from the same molecule: an immediate-release (IR) capsule for treating attacks as they happen, and an extended-release (XR) tablet for preventing them. The company has no approved products and therefore no product revenue, so the income statement is essentially research spending funded by equity raises.

Full PHVS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• HAE drivers: Plasma without the CSL overhang; Yield software as a razor-blade lever.
• PHVS drivers: The deucrictibant IR filing under FDA review; The CHAPTER-3 prophylaxis readout.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Customer concentration is the structural risk: plasma collection in the United States is consolidated into a handful of buyers, and the CSL departure showed how much revenue a single non-renewal can remove. For PHVS, the concentration risk is close to total: essentially all of the value sits in one molecule, and a complete response letter, a manufacturing or inspection issue, or a safety signal in longer follow-up would hit both indications at once.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick HAE if you believe its drivers more; PHVS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HAE and PHVS guides.

HAE. A little over three times sales is an unremarkable multiple for a medical-device company with high-margin recurring disposables, and it reflects several years in which reported growth was held down by the CSL transition rather than by demand. The August 2026 print was the first quarter in a while where reported and organic growth were the same number, which is what happens when the lost contract finally leaves the comparison. What the multiple is really pricing is whether mid single-digit organic growth is the ceiling or the floor.

PHVS. There is no revenue multiple to work with here, because there is no revenue: the valuation is a discounted view of what deucrictibant might sell if approved in both on-demand and prophylactic HAE. The financial statements are reported in euros while the shares trade in dollars, so the cash figure and the market cap are not directly comparable without converting. Second-quarter 2026 results were scheduled for release on August 19, 2026, after the figures above.

Headline figures (approximate, August 2026): HAE shows market cap ~$4.13B, revenue (ttm) ~$1.35B, share price ~$90.80, price / ttm sales ~3.1x; PHVS shows product revenue None. No approved products yet, cash and equivalents ~247 million euros at March 31, 2026, plus a ~$132 million follow-on closed after quarter end, r&d expense ~30.2 million euros in Q1 2026 (vs ~30.9 million a year earlier), net loss ~39.2 million euros in Q1 2026 (~0.60 euros per share).

HAE and PHVS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HAE and PHVS exposure against your real portfolio. It is not an investment adviser.